TCRX,TScan Therapeutics, Inc. | Healthcare

Healthcare

TCRX

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

TScan Therapeutics, Inc.TCRX

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

Market Cap

66.21M

Revenue (ttm)

2.82M

Net Income (ttm)

-127.50M

Shares Out

56.59M

EPS (ttm)

-2.25

PE Ratio

n/a

Forward PE

n/a

Dividend

n/a

Ex-Dividend Date

n/a

Volume

117,168

Open

1.160

Previous Close

1.130

Day's Range

1.140 - 1.185

52-Week Range

1.020 - 9.690

Beta

1.08

Analysts

Strong Buy

Price Target

9.83 (+740.17%)

Earnings Date

May 12, 2025

Description >

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer.

It is developing TSC-100 and TSC-101 that is in Phase I of clinical trial for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-204 that is in Phase I for the treatment of solid tumors.

The company also developing TSC-200, TSC-201, TSC-202, TSC-203, and TSC-205 for the treatment of solid tumors.

In addition, it engages in the developing vaccines for infectious diseases, such as SARS-CoV-2. The company has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer; and a collaboration agreement with Amgen to identify novel targets in Crohn's disease.

TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Latest News >

Eni Completes $1 Billion Alaska Asset Sale, Fast-Tracks Portfolio Goal: Details

Nov 4, 2024

Eni S.p.A. shares are trading higher on Monday. The company disclosed the successful completion of the sale of 100% of its Nikaitchuq and Oooguruk assets in Alaska to Hilcorp for a total value of $1 billion. The transaction, approved by all relevant authorities, aligns with Eni’s strategy to streamline its upstream portfolio by divesting non-core assets. This sale contributes to Eni’s...

Myriad Genetics Disputes Inclusion of GeneSight in UnitedHealthcare's Coverage Restriction

Nov 4, 2024

10:56 AM EST, 11/04/2024 (MT Newswires) -- Myriad Genetics ( MYGN ) said Monday that it strongly disagrees with UnitedHealthcare's decision to restrict coverage access to multi-gene panel pharmacogenetic tests, including Myriad's GeneSight test, under the commercial and individual exchange benefit plans. The updated policy, which takes effect on Jan. 1, is based on the rationale that there is insufficient...

LoanDepot, Smith Douglas Homes Form Joint Venture to Support Financing for New Home Buyers

Nov 4, 2024

10:56 AM EST, 11/04/2024 (MT Newswires) -- LoanDepot ( LDI ) and Smith Douglas Homes ( SDHC ) said Monday they established a joint venture called Ridgeland Mortgage to support financing for new home buyers. The joint venture will operate in Atlanta, Georgia; Houston, Texas; Birmingham and Huntsville, Alabama; Charlotte and Raleigh, North Carolina; and Chattanooga and Nashville, Tennessee, the...

Advance Auto Parts Completes Sale of Worldpac to Carlyle

Nov 4, 2024

10:59 AM EST, 11/04/2024 (MT Newswires) -- Advance Auto Parts ( AAP ) said Monday it has completed the previously announced $1.5 billion sale of Worldpac, its automotive parts wholesale distribution business, to Carlyle Group ( CG ) . Net proceeds from the sale are expected to be roughly $1.2 billion, the company added. Shares of Advance Auto Parts (...